In this study, 65 patients with cutaneous symptoms during NSAID
therapy were negative in the NSAID
Through systemic action, NSAIDS can increase the permeability of bowel mucosa [8, 9] (confirmed by scintigraphy with radioactive marker) as well, which induces increased protein losing into the bowel.
Our study demonstrated that 15% of these patients received one type of NSAID
during the study period.
Treatment with NSAIDs
following a first heart attack increases the risk of death in the first year after the heart attack, compared with patients who were not treated with NSAIDs
after their first heart attack.
However, in addition to gastrointestinal and renal side-effects, prophylactic NSAID
use may impede collagen synthesis and reduce tissue adaptation, predisposing the athlete to future injury.
Prevalence of prescriptions containing parenteral (IM route) preparations of NSAIDs
in this study is 9%, which is almost similar when compared to study conducted in Manipal where parenteral preparation of NSAID
prevalence was 8.
The most common NSAIDs
prescribed were Ibuprofen (23 percent) and Diclofenac (13.
were associated with an increased risk of death or recurrent heart attack, with diclofenac having the highest risk (nearly three times).
The incidence rate was 25 fractures per 1,000 person-years in the NSAID
group, 128 per 1,000 person-years in those on short-acting opioids, and 53 per 1,000 person-years in the group on long-acting opioids.
But when people have severe arthritis, that doesn't always do the trick, and an NSAID
The new data on CV risk, drawn from more than one million NSAID
users, is consistent with previous findings on NSAID
safety for people with cardiovascular disease.
use may further compromise renal blood flow by inhibiting prostaglandin-induced vasodilation and may cause ischaemic injury.